Adocia SA · EURONEXT:ADOC
Adocia SA — Investor Presentation (June 2021)
40 slides from Adocia SA's investor presentation, June 2021

Slide 1: Corporate Presentation
Corporate Presentation June 2021

Slide 2: Disclaimer
Disclaimer This corporate presentation (the “Presentation”) has The Presentation does not purport to contain well as the trends in the sector in which the Group been prepared by ADOCIA S.A. (the “Company” and, comprehensive or complete information about the operates, may differ materially from those

Slide 3: Highly experienced management team
Highly experienced management team Gérard Soula Olivier Soula Valérie PhD, MBA PhD, MBA Danaguézian Deputy General Manager, President & CEO Director of R&D Chief Financial Officer Co-founder Co-founder Jérémy Benattar Michael PharmD, Eng Nguyen Director of Marketing & Head of BD,US Strategy • Co-fou

Slide 4: Executive Summary
Executive Summary Our mission: to develop innovative treatments involving approved hormones 1 for the treatment of diabetes and obesity 2 Our business model: product licensing after proof-of-concept Our pipeline: 5 products with clinical proof-of-concept and 6 preclinical 3 stage projects Two patent

Slide 5: Adocia's vision: addressing metabolic diseases from hormonal to cell therapies
Adocia’s vision: addressing metabolic diseases from hormonal to cell therapies Scaffold for pancreatic β-cells replacement therapies Multi-hormonal combination for obesity and diabetes e.g. M1Pram, PramExe, drugs for Dual Hormones Artificial Pancreas Biobetters for Type 1 and Type 2 diabetes e.g. BC

Slide 6: A well-advanced pipeline with products ready to partner
A well-advanced pipeline with products ready to partner Preclinic Phase 1 Phase 2 Phase 3 Upcoming milestones BC Lispro Phase 3 in China expected in 2021 Ultra-Rapid Insulin U100 / U200 Phase 3 in USA and Europe in 2022 Insulins Combination BC Combo U200 Phase 1 expected in 2021 Long acting + Rapid

Slide 7: Diabetes and Obesity: worldwide chronic pandemics
Diabetes and Obesity: worldwide chronic pandemics 463 million people live with diabetes 650 million adults are obese in 20191 1,9bn are overweight 1 in 11 people 1 in 4 people affected Diabetes is closely linked to obesity • In the US, 65% of adults with type 13 diabetes and 85% of type 24 are overw

Slide 8: Two patented technology platforms
Two patented technology platforms Corporate Presentation 8

Slide 9: BioChaperone platform potentializes performance of insulins and other hormones
1 BioChaperone® platform (BC) potentializes performance 2 of insulins and other hormones BioChaperone® Proteins and peptides (insulin, amylin, GLP-1 RA, glucagon…) • Pharmaceutical excipient • 50 patents filed [BioChaperone® Protein] Complex Improved solubility Accelerated absorption Improved st

Slide 10: Adocia's Hydrogel scaffold for pancreatic β-cells therapy
1 Adocia’s Hydrogel scaffold for pancreatic β-cells therapy 2 Semipermeable Hydrogel scaffold Designed and synthetized by Adocia Islets Allogenic / stem-cell Macrophages, antibodies, etc… Glucose, oxygen, nutrients… Insulin Adocia’s goal is to propose a life saving therapy to insulino-resistant pati

Slide 11: Diabetes
Diabetes Corporate Presentation 11

Slide 12: BioChaperone Lispro
BioChaperone® Lispro The next best-in-class Rapid Acting Insulin for a tighter glycemic control Corporate Presentation 12

Slide 13: BC Lispro, a competitor in the Ultra-Rapid Insulins class
BC Lispro, a competitor in the Ultra-Rapid Insulins class Only 3 ultra-rapid insulins will compete in the $9bn1 prandial insulin market, addressing the needs of 34 millions mealtime insulins users (T1D + T2D): BC Lispro • Licensed to Tonghua Dongbao (THDB) for development & commercialization for Chi

Slide 14: BC Lispro has competitive advantages in the new Ultra-Rapid Insulin class
BC Lispro has competitive advantages in the new Ultra-Rapid Insulin class Post-meal glycaemia in T1D • Better efficacy profile for less hyperglycemia and less hypoglycemia (“Faster-in” / “Faster- out”) vs. comparators • Good tolerance for optimized daily use AUC0-2h: -61%* • Range of strengths (U100

Slide 15: BC Lispro development timelines
BC Lispro development timelines 2021 Phase 3 launch expected Pre-clinical data package, Sponsored and funded by 2024 – EMA/FDA dossier Tonghua Dongbao (THDB) PK/PD filing 10 Phase 1 & 2 studies 2025 – market launch 5 years of development 2033 – patent expiry 2022 Phase 3 Launch scheduled Looking for

Slide 16: BC Combo: basal-bolus insulin combination
BC Combo: basal-bolus insulin combination Insulins glargine & lispro Corporate Presentation 16

Slide 17: BC Combo is licensed to Tonghua Dongbao in China
BC Combo is licensed to Tonghua Dongbao in China • Targeting a $2.5bn1 global premix market • Focused on the Chinese market, where 65% of insulin use is premix first line • Licensed to Tonghua Dongbao for Chinese market2 o $40m upfront o $50m upcoming development milestones o Double-digit royalties

Slide 18: BC Combo combines simplicity of use and performance of modern insulins
BC Combo combines simplicity of use and performance of modern insulins: glargine and lispro Less hyperglycemia Less hypoglycemia Trial in 28 people with T1D (NCT#02514954); * p=3.10-3;**p=8.10-3 BC Combo offers better performance than Humalog Mix, current standard of care on the premix market Corpor

Slide 19: Multi-hormonal combinations
Multi-hormonal combinations Insulin in combination with other hormones Corporate Presentation 19

Slide 20: Adocia intends to deliver medical value for people with T1D and T2D requiring insulins
Adocia intends to deliver medical value for people with T1D and T2D requiring insulins Multi-hormonal combinations Medical M1Pram, BC LisPram/ benefits BC AsPram Ultra-Rapid Insulins BC Lispro, Fiasp®, Lyumjev® Rapid Acting Insulins Humalog®, Novolog® & biosimilars Human Insulins Animal Insulins Hum

Slide 21: M1Pram, BC LisPram / BC AsPram
M1Pram BC LisPram / BC AsPram Insulin-Amylin 2-in-1 products: a therapeutic breakthrough Corporate Presentation 21

Slide 22: Glycemic control requires the synchronized action of insulin and amylin
Glycemic control requires the synchronized action of insulin and amylin Meal Without diabetes Pancreas Insulin Level of secretion (relative scale) Amylin Insulin Glucagon Produced 0 1 2 3 4 5 6 Produced Glucagon by α-cells Time (hours) by β-cells Meal With diabetes Level of secretion Glucagon is dys

Slide 23: Symlin (pramlintide) was approved by FDA in 2005 as an adjunct to insulin treatment
Symlin® (pramlintide, an amylin analog) was approved by FDA in 2005 as an adjunct to insulin treatment for T1D and T2D The amylin effects in physiology The evidences demonstrated by pramlintide Activates amylin receptors in different brain areas Satiety Improvement of HbA1c Protects cognitive

Slide 24: Adocia is developing insulin-amylin combinations for pen and pump
Adocia is developing insulin-amylin combinations for pen and pump Optimal product profile for MDI in pen Optimal product profile for pump Regular insulin analog + Pram Rapid insulin analog + Pram M1Pram BC LisPram BC AsPram Q1 2022: Phase 2 T1D results Q2 2021: Launch Phase 1 T1D MDI: Multiple Daily

Slide 25: Promising Phase 1b results of M1Pram in pen vs Novolog
Promising Phase 1b results of M1Pram in pen vs Novolog Phase 1b – CT038: n=40 T1D 3-week outpatient trial - M1Pram vs. Novolog (Part B n=16; High dose of insulin) Average glycemia Weight Time In Range 164 0,5 16,2 162 0,4 16 0 15,8 160 -7 mg/dL -2 kg 15,6 +58 min -0,5 Hours 158 mg/dL p=0,01 p=0,0065

Slide 26: M1Pram offers better glycemic control and weight loss
M1Pram offers better glycemic control and weight loss M1Pram leverages pramlintide’s clinical benefits “This combination has the potential to Targeted phase 2 results: finally deliver on the promise of pramlintide for a large number of patients.” HbA1c decrease: [-0,3% ; -0,5%] Prof. Robert Ratner

Slide 27: BC LisPram: the optimal combination for pumps
BC LisPram: the optimal combination for pumps Clinical Proof-of-Concept established at Mc Gill University, Canada, by Dr. A. Haidar, comparing Lispro in one pump vs Lispro and Pramlintide administered simultaneously in two separate pumps, over one month1 n=29 T1D Results • 10% improvement of Time in

Slide 28: Cell Therapy
Cell Therapy Innovative Scaffold for Pancreatic Cell Therapy Corporate Presentation 28

Slide 29: Adocia developed an innovative graft based on a proprietary hydrogel
Adocia developed an innovative graft, based on a proprietary hydrogel to protect and host β-cells Hydrogel scaffold Graft Organoid Islets sourcing (Allogenic/stem-cell) External source Adocia’s goal is to propose a life saving therapy to insulino-resistant patients Corporate Presentation 29

Slide 30: Development achievements: innovative hydrogel
Development achievements Innovative Hydrogel Well tolerated Insulin secretion Encapsulated Islets in response to glucose Naked Islets Long term stability and fully retrievable Patents application filed 3G 15G 3G 6 Islets encapsulation Normalized insulin secretion 5 Simple and cell-friendly p

Slide 31: Obesity
Obesity Corporate Presentation 31

Slide 32: PramExe
PramExe For a personalized obesity treatment: a paradigm shift Corporate Presentation 32

Slide 33: A new paradigm: a patient centric approach for obesity treatment
A new paradigm: a patient centric approach for obesity treatment CURRENT PARADIGM ADOCIA’S PARADIGM Long acting GLP-1 are being developed to The patient is wearing a patch-pump limit the number of injections to deliver short acting hormones However, despite efficacy, GLP-1 goes along It provides the

Slide 34: Attractiveness of short-acting hormones in pump
Attractiveness of short-acting hormones in pump 2 days infusion 1 day off 3 days infusion Concentration 1x Patient can: Concentration 2x Concentration 4x • Intensify the treatment by increasing the dosage to obtain maximum results • Stop temporarily by switching it off, to suspend immediately unwant

Slide 35: PramExe, a combination of pramlintide and exenatide
PramExe, a combination of amylin analog (pramlintide) and GLP-1 receptor agonist (exenatide): a paradigm shift for people with obesity Weight loss & satiety Pramlintide Improves glycemia Expected outcomes Well-being • Significant weight loss PramExe • Good tolerance profile • Personalized mana

Slide 36: Financial & news flow
Financial & news flow Corporate Presentation 36

Slide 37: News flow
News flow BC Lispro M1Pram PramExe – BC GluExe • In China: Phase 3 launch • Phase 2 study in TD1 in MDI • Fisrt-In-Human Q2 2022 expected in 2021 (Multiple Daily Injection) ongoing • In USA/EU: Phase 3 launch scheduled in 2022 • Results expected Q1 2022 Cell Therapy • Large animal POC Q4 2021 BC Com

Slide 38: Key financials & shareholder information
Key financials & shareholder information (as of December 2020) Key financials features1 Shareholder ownership Market information Already received • Listed on Euronext Paris (ADOC) • €85m raised since inception Soula Family • 7m shares outstanding • $120m received from partnership 22,1% • ADR program

Slide 39: Summary
Summary • Adocia has 5 ready-to-license products with clinical proof-of-concept based on its proprietary BioChaperone® platform • The strategic partnership with Tonghua Dongbao is progressing well with still up to $85m in development milestone to come for BC Combo and BC Lispro for China and other A

Slide 40: Thank you for your kind interest
Thank you for your kind interest 115 avenue Lacassagne 69003 Lyon – FRANCE Ph.:+33 4 72 610 610 contact@adocia.com
Source: Internet Archive copy of adocia.com
More decks from Adocia SA
Q3 2026 Earnings Presentation19 slides · Nov 2, 2026
Investor Presentation (November 2026)33 slides · November 2026
Investor Presentation (June 2026)43 slides · June 2026
Investor Presentation (March 2026)43 slides · March 2026
Investor Presentation (November 2025)42 slides · November 2025
Shareholder Meeting (June 2025)85 slides · Jun 11, 2025